Hemophilia
Hemophilia A and B are hereditary bleeding disorders caused by deficiencies in factor VIII (FVIII) and factor IX (FIX), respectively. Hemophilia is often treated with replacement factors (ex. recombinant or plasma-derived FVIII or FIX), or bypassing agents (ex. recombinant activated factor VIIa, anti-inhibitor coagulation complex, or recombinant porcine FVIII). We have shown effects of novel hemostatic agents on fibrin formation, structure, and stability, including recombinant factor VIIa (NovoSeven) (, , ) and . We are continuing these investigations to understand how replacement and bypassing therapies modify fibrin quality, and identify new, improved drugs to reduce bleeding in persons with hemophilia.